<DOC>
	<DOCNO>NCT00574171</DOCNO>
	<brief_summary>The purpose study find effective combination second line treatment colorectal cancer spread one part body another ( metastasize ) metastasize consider inoperable ( unable remove surgery ) . The side effect survival experience subject receive drug also evaluate . This phase II research study .</brief_summary>
	<brief_title>Phase II Trial Lapatinib &amp; Capecitabine Patients With Refractory Advanced Colorectal Adenocarcinoma</brief_title>
	<detailed_description>1 . To evaluate response rate lapatinib capecitabine combination patient metastatic colon rectal cancer . 2 . To evaluate toxicity tolerability lapatinib capecitabine population . 3 . To determine overall survival disease free survival lapatinib capecitabine .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Age &gt; 18 year Pathologically confirm , locally advanced metastatic adenocarcinoma colon rectum Patients must progression disease prior therapy oxaliplatincontaining irinotecan contain regimen Proper radiographic documentation measurable disease use RECIST criterion ECOG performance status ( PS ) 0 1 Laboratory parameter : Hgb : ≥ 9.0 g/dl ANC ≥ 1500/ul Platelet ≥ 100,000/ul Creatinine ≤ 2x ULN OR Creatinine clearance ≥ 30 mg/ml Bilirubin ≤ 2x ULN AST ≤ 2x ULN 5X ULN liver metastases present Patient sign informed consent Toxicities prior therapy ( except alopecia neuropathy ) must resolve grade 1 good prior enrollment Administration one prior systemic chemotherapy metastatic disease Pregnant breastfeed woman : female patient must agree use effective contraception , must surgically sterile , must postmenopausal . Male patient must agree use effective contraception surgically sterile . The definition effective contraception base judgment principal investigator designate associate . All atrisk female patient must negative serum pregnancy test within 7 day prior randomization . Active inflammatory bowel disease , significant bowel obstruction , chronic diarrhea ( grade 2 ) . Known human immunodeficiency virus ( HIV ) positivity acquiredimmunodeficiencysyndrome ( AIDS ) relate illness . No previous concurrent malignancy allow except adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , cancer patient diseasefree 3 year . Known CNS metastases Prior therapy specifically directly target EGFR pathway Significant history uncontrolled cardiovascular disease , define : History uncontrolled symptomatic angina History arrhythmia require medication , clinically significant , exception asymptomatic atrial fibrillation require anticoagulation Myocardial infarction &lt; 6 month prior study entry Cerebrovascular accident &lt; 6 month prior study entry Uncontrolled symptomatic congestive heart failure Ejection fraction institutional normal limit Any cardiac condition , opinion treat physician , would make protocol unreasonably hazardous patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>